 | Up a level |
Haber, Philipp K; Castet, Florian; Torres-Martin, Miguel; Andreu-Oller, Carmen; Puigvehí, Marc; Maeda, Miho; Radu, Pompilia; Dufour, Jean-Francois; Verslype, Chris; Czauderna, Carolin; Marquardt, Jens U; Galle, Peter R; Vogel, Arndt; Bathon, Melanie; Meyer, Tim; Labgaa, Ismail; Digklia, Antonia; Roberts, Lewis R; Mohamed Ali, Mohamed A; Mínguez, Beatriz; ... (2023). Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma. Gastroenterology, 164(1), 72-88.e18. Elsevier 10.1053/j.gastro.2022.09.005
Galle, Peter R; Kudo, Masatoshi; Llovet, Josep M; Finn, Richard S; Karwal, Mark; Pezet, Denis; Kim, Tae-You; Yang, Tsai-Sheng; Lonardi, Sara; Tomasek, Jiri; Phelip, Jean-Marc; Touchefeu, Yann; Koh, Su-Jin; Stirnimann, Guido; Liang, Kun; Ogburn, Kenyon D; Wang, Chunxiao; Abada, Paolo; Widau, Ryan C and Zhu, Andrew X (2021). Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology. Liver international, 41(11), pp. 2759-2767. Wiley 10.1111/liv.14994
Llovet, Josep M; Villanueva, Augusto; Lachenmayer, Anja; Finn, Richard S (2015). Erratum for Advances in targeted therapies for hepatocellular carcinoma in the genomic era. [Nat Rev Clin Oncol. 2015]. Nature reviews - clinical oncology, 12(8), p. 436. Nature Publishing Group 10.1038/nrclinonc.2015.121
Llovet, Josep M; Villanueva, Augusto; Lachenmayer, Anja; Finn, Richard S (2015). Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nature reviews - clinical oncology, 12(7), pp. 408-424. Nature Publishing Group 10.1038/nrclinonc.2015.103
